Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 03, 2019 09:00 ET | Source: Aptose Biosciences, Inc.

Aptose Appoints Jotin Marango, M.D., Ph.D. as Chief Business Officer

SAN DIEGO and TORONTO, June 03, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the...
June 03, 2019 08:38 ET | Source: Aptose Biosciences, Inc.

Aptose Announces Closing of Public Offering of Common Shares

SAN DIEGO and TORONTO, June 03, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced the closing of its previously announced...
May 31, 2019 08:00 ET | Source: Aptose Biosciences, Inc.

Aptose to Present at the Jefferies 2019 Healthcare Conference

SAN DIEGO and TORONTO, May 31, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target the...
May 30, 2019 09:01 ET | Source: Aptose Biosciences, Inc.

Aptose Announces Pricing of Public Offering of Common Shares

SAN DIEGO and TORONTO, May 30, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that it priced its previously announced...
May 29, 2019 16:22 ET | Source: Aptose Biosciences, Inc.

Aptose Announces Proposed Public Offering of Common Shares

SAN DIEGO and TORONTO, May 29, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that it has commenced an underwritten public...
May 24, 2019 17:43 ET | Source: Aptose Biosciences, Inc.

Aptose Biosciences Establishes New At-The-Market Facility

SAN DIEGO and TORONTO, May 24, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated...
May 16, 2019 10:02 ET | Source: Aptose Biosciences, Inc.

Aptose to Present New Preclinical Data for CG-806 at the 24th Congress of The European Hematology Association

SAN DIEGO and TORONTO, May 16, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated...
May 13, 2019 08:15 ET | Source: Aptose Biosciences, Inc.

Aptose to Present at May Investor Conferences

SAN DIEGO and TORONTO, May 13, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target the...
May 10, 2019 19:24 ET | Source: Aptose Biosciences, Inc.

Aptose Announces Commencement of Previously Announced $20.0 Million Common Share Purchase Agreement with Aspire Capital Fund, LLC

SAN DIEGO and TORONTO, May 10, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated...
May 07, 2019 16:01 ET | Source: Aptose Biosciences, Inc.

Aptose Reports Results for the First Quarter Ended March 31, 2019

─ Patient Dosed at Second Dose Level in APTO-253 Clinical Trial ─ ─ Patient Screening Initiated for CG-806 Clinical Trial ─ Conference Call and Webcast at 5pm EDT Today SAN DIEGO and TORONTO, May...